Reaction

Ear Pruritus reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,436 reports · 81 co-occurring drugs

As of the last recalculation, Ear Pruritus appears in 3,436 FAERS reports alongside 81 co-occurring drug terms. The strongest observed disproportionality signal is OSELTAMIVIR PHOSPHATE (PRR 54.6).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Oseltamivir Phosphate	207	54.6	55.0
Diphenhydramine Hydrochloride Capsule, Liquid Filled	143	42.3	42.5
Ceftriaxone Sodium	203	34.0	34.2
Diphenhydramine	318	33.5	33.7
Ocrelizumab	301	32.1	32.3
Mepolizumab	243	31.8	32.0
Diphenhydramine Hydrochloride	596	26.1	26.2
Azithromycin Monohydrate	158	24.0	24.1
Methylprednisolone	457	22.9	23.0
Dimenhydrinate	38	21.8	21.9
Omalizumab	267	20.5	20.6
Azithromycin	115	17.9	17.9
Rituximab	525	17.6	17.6
Methylprednisolone Sodium Succinate	126	17.0	17.1
Methylprednisolone Acetate	22	16.7	16.8
Montelukast Sodium	296	16.0	16.1
Hydrocortisone Sodium Succinate	23	14.9	14.9
Budesonide	137	14.6	14.7
Acetaminophen 500Mg	499	13.7	13.7
Acetaminophen Tablet Extended Release	497	13.6	13.7
Pain Reliever	497	13.6	13.6
Azithromycin Dihydrate	121	12.9	12.9
Albuterol	238	12.8	12.9
Acetaminophen	578	9.2	9.2
Fesoterodine Fumarate	16	9.0	9.0
Alemtuzumab	25	7.9	7.9
Fluticasone Furoate	15	7.5	7.5
Rizatriptan Benzoate	12	7.2	7.2
Diphenhydramine Hcl	13	7.1	7.1
Albuterol Sulfate	313	6.9	6.9
Prednisone	500	6.9	6.9
Desloratadine	12	6.8	6.8
Iohexol	9	6.6	6.6
Tiotropium Bromide Inhalation Spray	12	6.5	6.5
Acetaminophen, Guaifenesin, And Phenylephrine Hydrochloride	160	6.3	6.3
Diroximel Fumarate	12	6.1	6.1
Cetirizine Hydrochloride Allergy	28	5.6	5.6
Cetirizine Hydrochloride Tablets	28	5.6	5.6
Ceftriaxone	30	5.6	5.6
Erythromycin	17	5.5	5.5
Acetaminophen, Chlorpheniramine Maleate, Phenylephrine Hcl	42	5.1	5.1
Crisaborole	8	5.1	5.1
Budesonide And Formoterol Fumarate Dihydrate	74	4.7	4.7
Azelastine	13	4.4	4.4
Rimegepant Sulfate	9	4.3	4.3
Fluticasone Furoate And Vilanterol Trifenatate	25	4.2	4.2
Sodium Chloride	54	4.2	4.2
Minocycline	8	4.2	4.2
Sodium Chloride Tablet	50	4.2	4.2
Sodium Chloride Tablets	50	4.2	4.2
Infliximab-Dyyb	19	4.0	4.0
Tocilizumab	73	3.9	3.9
Fexofenadine Hydrochloride	14	3.9	3.9
Baclofen	54	3.8	3.8
Loratadine And Pseudoephedrine Sulfate	5	3.8	3.8
Montelukast	52	3.8	3.8
Levocetirizine Dihydrochloride	15	3.8	3.8
Loratadine Tablet	33	3.8	3.8
Bimekizumab	13	3.7	3.7
Tizanidine	14	3.6	3.6
Desoximetasone	11	3.5	3.5
Eptinezumab-Jjmr	5	3.3	3.3
Methoxy Polyethylene Glycol-Epoetin Beta	6	3.3	3.3
Ofatumumab	18	3.3	3.3
Loratadine	57	3.2	3.2
Bosutinib	4	2.7	2.7
Vilazodone Hydrochloride	4	2.6	2.6
Minoxidil	18	2.4	2.4
Erlotinib Hydrochloride	5	2.4	2.4
Minoxidil Foam 5% (Womens)	13	2.4	2.4
Risankizumab-Rzaa	30	2.2	2.2
Dimethyl Fumarate	40	2.0	2.0
Natalizumab	53	1.8	1.8
Medroxyprogesterone Acetate	13	1.6	1.6
Cannabidiol	6	1.6	1.6
Dupilumab	118	1.5	1.5
Ixekizumab	8	1.3	1.3
Alirocumab	5	1.2	1.2
Nirmatrelvir And Ritonavir	10	1.1	1.1
Lifitegrast	3	1.1	1.1
Pomalidomide	17	1.0	1.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.